Plasma PGE-2 levels and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC) by Hidalgo, Giovanna E et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Molecular Cancer
Open Access Molecular Cancer  2002,  1 x Research
Plasma PGE-2 levels and altered cytokine profiles in adherent 
peripheral blood mononuclear cells in non-small cell lung cancer 
(NSCLC)
Giovanna E Hidalgo, Li Zhong, Dennis E Doherty and 
Edward A Hirschowitz*
Address: Division of Pulmonary and Critical Care Medicine, Lexington Veteran's Administration Medical Center, University of Kentucky, Chandler 
Medical Center, 800 Rose Street, Lexington, Kentucky 40536, USA
E-mail: Giovanna E Hidalgo - ghida2@pop.uky.edu; Li Zhong - lzhon2@uky.edu; Dennis E Doherty - dedohe0@pop.uky.edu; 
Edward A Hirschowitz* - eahirs2@uky.edu
*Corresponding author
Keywords: Non-small cell lung cancer, PGE-2, IL10
Abstract
Introduction: PGE-2 is constitutively produced by many non-small cell lung cancers (NSCLC) and
its immunosuppressive effects have been linked to altered immune responses in lung cancer. We
asked whether elevated levels of plasma PGE-2 correlated with monocyte IL10 production in the
NSCLC environment. Looking for correlation in NSCLC patient blood we assayed plasma from
NSCLC patients for PGE2 and IL10; we further evaluated production of IL10 by adherent
mononuclear cells from a subset of these patients looking for an altered cytokine profile.
Results: Our initial in vitro experiments show that monocyte IL10 induction correlates with tumor
cell PGE-2 production, confirming similar reports in the literature. Data show plasma PGE-2 levels
in 38 NSCLC patients are elevated compared to normal controls. Plasma IL10 levels were not
significantly elevated; however, adherent monocytes derived from NSCLC patient blood did
produce significantly more IL10 in 24 hr primary culture than those from normal controls (p <
0.01). The association of elevated plasma PGE-2 and monocyte derived IL-10 was not significant.
Conclusions: Elevated plasma PGE-2 and monocyte IL10 production are associated with NSCLC.
The biological significance to elevated PGE-2 levels in NSCLC are unclear. Further investigation of
each as a nonspecific marker for NSCLC tumor is warranted.
Background
One mechanism by which tumors evade immune destruc-
tion is through cytokine production or induction [1].
Prostaglandin E-2 (PGE-2), constitutively produced by
many NSCLC has been identified as one factor that has di-
rect immunosuppressive properties and is known to in-
duce IL10 in mononuclear cells [2–7]. IL10 is a dominant
immunosuppressive cytokine found in the NSCLC envi-
ronment known to directly affect T cell-mediated immu-
nity [2–12]. Both PGE-2 and IL10 have been shown to
suppress antigen presentation, to suppress cytotoxic T cell
(CTL) responses, and to inhibit cytokine production by T
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cells and antigen presenting cells, perhaps most impor-
tantly IL12, that plays a central role in initiation and po-
tentiation of cellular immune responses [2–7], [11–19].
We asked whether PGE-2 levels and/or IL10 levels were el-
evated in plasma of NSCLC patients, whether monocytes
from NSCLC patients produce more IL10 than normals,
and whether there was correlation within our findings. As
an additional in vitro correlate, we evaluated differences in
IL10 production by normal adherent peripheral blood
mononuclear cells cultured in conditioned media from
cell lines that produce variable amounts of PGE-2.
Results
PGE-2 produced by tumor cell lines correlated with IL10 
production by normal donor adherent PBMC
To confirm observations from the literature, supernatants
from 6 different NSCLC cell lines producing variable
amounts of PGE-2 (ranging from 100 pg/ml/5 × 105 cells
to >50,000 pg/ml/5 × 105 cells) were compared directly
for their ability to induce IL10 in adherent mononuclear
cells. Each cell line induced IL10 in adherent mononu-
clear cells that was greater than control. This relative in-
crease in IL10 correlated with PGE-2 produced by each
cell line (p < 0.05).(Figure 1).
PGE-2 levels in plasma of individuals with NSCLC
Two separate assays yielded similar elevations in plasma
levels of PGE2 above normals. Each assay used different
sets of normals for comparison. Significant differences
were seen when comparing measurements from 38
NSCLC samples to 9 normals (234+/-40 vs.519+/-54; p =
0.0167) and 27 NSCLC patient samples to 16 normals
(846+/-62 vs. 1838 +/-213; p = 0.0011) (Figure 2). Abso-
lute measures of PGE-2 differed between assays that pre-
Figure 1
Production of PGE-2 and induction of IL10 by NSCLC tumor cell lines. Supernatants from 6 established cell lines and control
cell line 293 (5 × 105/ml) were assayed for PGE-2 over 24 hr by ELISA. Data are presented as mean of triplicate samples and
are expressed as pg/ml/5 × 105 cells. Supernatants were transferred to adherent mononuclear cells from healthy volunteers
(106/ml) and IL10 was assayed in supernatants at 24 hr. Data are expressed as mean +/- SEM.
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vented the pooling of results; relative values may reflect
differences in sample handling or assay conditions, or dif-
ferences in ELISA kits themselves. Plasma IL10 levels
measured in 29 patient samples were not significantly el-
evated above controls (6.6 ± 4.6 vs. 3.9 ± 3.6; p > 0.1; not
shown). PGE-2 levels did not correlate with stage or his-
tology (p > 0.1 all comparisons).
Cytokine profiles of adherent mononuclear cells from 
NSCLC patients
Adherent cells, predominantly mononuclear phagocytes,
from 13 individuals were evaluated for IL10 production.
Data show adherent mononuclear cells from NSCLC pa-
tients produced baseline levels of IL10 significantly great-
er than those of normal volunteers (40 ± 25 vs. 574 ± 127;
p < 0.01; Figure 3). IL10 production did not correlate with
stage or histology (not shown).
Correlation of PGE-2 levels and IL10 production from ad-
herent mononuclear cells
Paired comparisons of plasma PGE-2 levels and mononu-
clear cell IL10 was possible in 11 patient samples. Paired
comparisons in patient sample did not reach statistical
significance (p > 0.1), although in a subset of 9 patients,
excluding 2 samples with the highest PGE-2 levels, a pos-
itive correlation of PGE-2 levels and IL10 production was
apparent (p < 0.05; Figure 4). There was no simple expla-
nation for these outliers, nor rationale for excluding these
samples. There was a significant correlation between PGE-
2 levels and IL10 production in normal samples (p <
Figure 2
Plasma levels of prostaglandin E-2 (PGE-2) in individuals with NSCLC. Two separate assays measuring PGE-2 levels in NSCLC
patients and normal controls. One assay measured 38 NSCLC plasma samples and 9 normal controls, the other, 27 NSCLC
patient samples compared to a separate set of 16 normals; both assays show similar results. The data are presented as mean ±
standard error of the mean.
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0.05), but combining normals and patient data did not
strengthen the statistical observations.
Discussion
COX-2 is an inducible enzyme upregulated in inflamma-
tory states [20,21]. Notably, many NSCLC and what have
been characterized as "premalignant" lung lesions have
been shown to constitutively express the COX-2 enzyme
and produce prostaglandin E-2 (PGE-2), the primary
product of the COX-2 pathway [22–26]. Importantly,
PGE-2 production by tumor cells has been linked to tu-
mor-induced immunosuppression in NSCLC [2–5]. PGE-
2 has been shown to directly suppress T cell mediated im-
munity, the primary effector against tumor cells, at a vari-
ety of levels [2–7]. Further, PGE-2 has been shown to
induce the IL10 in mononuclear cells [4,5]. IL10 is a
prominent immunosuppressive cytokine that may have a
dominant role in preventing innate antitumor responses
in the NSCLC environment [2–5], [8–19]. Among myriad
suppressive effects on T cells and antigen presenting cells,
IL10 is known to inhibit IL12 production [14–18]. IL12
plays a key role in the initiation and potentiation of cellu-
lar immune responses and alteration of the IL12 produc-
ing function in circulating mononuclear phagocytes may
be a critical factor in suppressed T cell immunity to
NSCLC [27,28].
We evaluated both PGE-2 and IL10 in plasma of NSCLC
patients finding only PGE-2 to be significantly elevated
above controls. Elevations were independent of stage of
Figure 3
IL10 production by adherent mononuclear cells from individuals with NSCLC and normals. 106 adherent cells/ml from 13 indi-
viduals with various stage NSCLC and 8 healthy volunteers were incubated in serum containing culture medium for 24 hr and
assayed for IL10 and by ELISA. Data are presented as mean ± standard error of the mean.
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disease or tumor histology. Data also show mononuclear
phagocytes from NSCLC patients produce significantly
more IL10 over 24 hr in primary culture than controls,
consistent with reports of altered cytokine profiles of ad-
herent mononuclear cells from breast cancer patients
[29]. Although in vitro experiments suggest there could be
a direct link between elevated plasma PGE-2 levels and in-
creased IL10 production by adherent mononuclear cells
in NSCLC, the measurements of patient samples do not
support a simple causal relationship. The correlation seen
in a subset of 9/11 patient samples may reflect only the
presence of underlying malignancy, however, it is tempt-
ing to speculate on the physiologic relationship between
the two.
PGE-2 can be induced by a number of inflammatory con-
ditions, however no single factor, other than cancer, is
likely to account for the significant differences seen in this
series. Absolute values of PGE-2, that may vary with differ-
ent assays, are likely less important than the observed dif-
ferences between NSCLC and normals. The lack of
association with disease stage or histology, and the non-
specific production of PGE-2 by multiple cell types, may
limit the usefulness of PGE-2 as a specific, independent
marker for NSCLC.
Apart from standardized measurement of PGE-2 as a
marker for disease, a biologically relevant aspect of elevat-
ed PGE-2 would be in the association with altered im-
mune profile of mononuclear phagocytes, specifically
IL10 induction. Importantly, serum IL10 levels were es-
tablished as an independent marker for disease and re-
sponse to therapy by De Vita et al [10]. The source of the
IL10 in that series was thought to be from mononuclear
Figure 4
PGE-2 levels and IL10 production by adherent peripheral blood mononuclear cells in NSCLC. Shown is a regression analysis of
PGE-2 levels and IL10 production by mononuclear phagocytes from 11 individuals with NSCLC. Two separate regression lines
indicate significance of the correlation including two outliers (dashed line; p > 0.1) and excluding two outliers (solid line; p <
0.05). Outliers are filled circles inside the box as indicated.
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cells. Based on the observations and conclusions of these
investigators, and the measurable increases in IL10 pro-
duction by mononuclear phagocytes derived from NSCLC
patients compared to controls, plasma levels of IL10 from
these patients might be expected to also be elevated. In the
current series, however, there was no difference between
patient and control plasma IL10 levels. The reasons for
this discrepancy are unclear, and may be related to differ-
ences in handling/processing samples or differences in the
sensitivity of the ELISAs used in the studies. Further, there
was no significant correlation between IL10 production
by mononuclear cells and disease stage, as might be in-
ferred from the previously mentioned studies. There was
no correlation with histologic type of lung cancer.
Conclusions
Plasma PGE-2 levels may be a nonspecific marker for
NSCLC and warrants further investigation. In contrast,
plasma IL10 levels did not appear to be sensitive markers
in our studies; IL10 production by circulating mononu-
clear cells, however appears to be associated with disease.
The reasons for IL10 production by mononuclear cells in
NSCLC are speculative and may be varied. Plasma PGE-2
may contribute but cannot be simply and directly linked.
Methods
Cell lines
Six established NSCLC cell lines (UKY-104, NCI-460,
NCI-820, NCI-1155, NCI-1355, and A549) were evaluat-
ed. Cell line UKY-104 is an adenocarcinoma established
in primary culture from a malignant pleural effusion. Cell
lines NCI-460 and NCI-1155 are large cell carcinomas,
NCI-820 is a bronchoalveolar type NSCLC, NCI-1355 is
an adenocarcinoma, all established at the National Can-
cer Institute (gift of H. Oie, NCI, National Institutes of
Health, Bethesda, MD). A549 is an undifferentiated lung
carcinoma and was purchased from American Type Cul-
ture Collection (ATCC, Rockville, MD). All cells were
maintained in RPMI complete media (10 % fetal bovine
serum, 50 units/ml penicillin G and 50 mg/ml streptomy-
cin; Gibco BRL Grand Island, NY). 293, a human embry-
onic kidney cell line was used as a control.
IL10 production by adherent PBMC from normal donors
Adherent monocytes, derived from whole blood of nor-
mal donors were purified from peripheral blood by lysing
red blood cells using Red Blood Cell Lysis Solution (Sig-
ma, St Louis, MO) and Ficoll Hypaque density separation
technique. Adherent mononuclear cells were separated
from granulocytes and nonadherent mononuclear cells (T
cells, B cells Natural Killer cells) by 4 hour adherence step.
106 cells/ml were plated in a 24 well culture dish for 24 hr
in tumor cell or control cell conditioned media then su-
pernatants were assayed for IL10 by ELISA (R&D).
Human subjects
Following informed consent, peripheral blood was ob-
tained from individuals with histologically confirmed
NSCLC. None of the subjects had concomitant illness
such as infection and none of the subjects in this series
were taking anti-inflammatory medications.
Plasma cytokines in individuals with NSCLC
Plasma was separated from cells by centrifugation and cry-
opreserved at -80° until use. PGE-2 and IL10 levels were
measured in 38 NSCLC patients and compared to that
from healthy volunteers by ELISA (R&D, Minneapolis,
MN). PGE-2 levels were measured in two separate assays:
the first compared 38 NSCLC patient samples to 9 nor-
mals; the second compared 27 patient samples to a differ-
ent set of 16 normals. Stage distribution included 11 stage
I or II, 15 stage IIIa/b, and 13 stage IV. Four of 10 stage 4
patients donated blood samples during follow-up ap-
pointments in between cycles of chemotherapy. One indi-
vidual was seen for local recurrence of primary disease
(stage IV), all other samples were drawn at the time of in-
itial diagnosis. Histologies included 13 squamous cell, 12
adenocarcinoma, one adeno/squamous cell, and 12 un-
specified NSCLC (undifferentiated or poorly differentiat-
ed non-small cell carcinoma) because specific cell type
was not discernable from available biopsies.
Cytokine profile of adherent PBMC from individuals with 
NSCLC
In 13 individual samples adequate numbers of peripheral
blood mononuclear cells were available for processing
(stage I-II n = 3; stage IIIa/b n = 6; stage IV n = 4). Adherent
PBMC were purified from peripheral blood as above. 106
adherent mononuclear cells/ml were incubated in a 24
well culture plate in complete RPMI and supernatant was
evaluated at 24 hr for basal production of IL10 by ELISA
(R&D). Plasma and mononuclear cells were available for
evaluation in 11 of 29 patient plasma samples.
PGE-2 production by established cell lines in vitro and gen-
eration of tumor cell conditioned media
Tumor cell lines or control cell line 293 were plated in a
24 well culture dish (5 × 105/ml) in complete media × 24
hr. Supernatants were assayed for PGE-2 by ELISA (R&D).
Tumor cell conditioned media (CM) was supernatant of
cells cultured × 24 hr in RPMI complete media at a density
of 5 × 105/ml. All conditioned media was filtered through
a 0.22 um filter prior to use.
Statistical analysis
Comparisons among individual patient samples were
made using paired t-test and all other comparisons were
made by ANOVA.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/5
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